Abacavir
- Generic Name
- Abacavir
- Brand Names
- Epzicom, Kivexa, Triumeq, Trizivir, Ziagen
- Drug Type
- Small Molecule
- Chemical Formula
- C14H18N6O
- CAS Number
- 136470-78-5
- Unique Ingredient Identifier
- WR2TIP26VS
- Background
Abacavir (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS. Chemically, it is a synthetic carbocyclic nucleoside and is the enantiomer with 1S, 4R absolute configuration on the cyclopentene ring. In vivo, abacavir sulfate dissociates to its free base, abacavir.
- Indication
Abacavir is indicated in combination with other anti-retroviral agents for the treatment of HIV-1 infection. It is available in a combination product alongside dolutegravir and lamivudine for the treatment of adult and pediatric patients with HIV-1 who weigh ≥10 kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Study of Options for Second-Line Effective Combination Therapy (SELECT)
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Abacavir/lamivudine/zidovudineDrug: Abacavir/lamivudine
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 515
- Registration Number
- NCT01352715
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
🇿🇦Soweto ACTG CRS (12301), Johannesburg, South Africa
ZIAGEN® Post-marketing Surveillance
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2018-06-19
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 671
- Registration Number
- NCT01205243
- Locations
- 🇰🇷
GSK Investigational Site, Incheon, Korea, Republic of
Treatment Options for Protease Inhibitor-exposed Children
- Conditions
- HIV/AIDSHIV Infections
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 300
- Registration Number
- NCT01146873
- Locations
- 🇿🇦
Rahima Moosa Mother and Child Hospital, Johannesburg, Gauteng, South Africa
Raltegravir Switch for Toxicity or Adverse Events
- Conditions
- Antiretroviral TherapyHIV/AIDSHIV Infections
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-02-04
- Lead Sponsor
- Catholic University of the Sacred Heart
- Target Recruit Count
- 40
- Registration Number
- NCT00958100
- Locations
- 🇮🇹
Policlinico A. Gemelli, Rome, Italy
Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)
- Conditions
- HIVHIV Infections
- Interventions
- Drug: emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)Drug: emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 454
- Registration Number
- NCT00928187
- Locations
- 🇧🇫
Day Hospital, CHU Sanou Souro, Bobo Dioulasso, Burkina Faso
🇨🇲Day Hospital, Central Hospital, Yaounde, Cameroon
🇸🇳Clinical Research and Training Center, Fann Hospital, Dakar, Senegal
A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Tibotec Pharmaceuticals, Ireland
- Target Recruit Count
- 12
- Registration Number
- NCT00915655
A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe
- Conditions
- AIDS-related Kaposi's Sarcoma
- Interventions
- Drug: abacavir/3TC/zidovudine
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2014-10-30
- Lead Sponsor
- Parirenyatwa Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT00834457
- Locations
- 🇿🇼
University of Zimbabwe College of Health Sciences Department of Medicine, Harare, Zimbabwe
A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2008-12-01
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Janssen Sciences Ireland UC
- Target Recruit Count
- 54
- Registration Number
- NCT00799864
Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2009-11-18
- Lead Sponsor
- St Stephens Aids Trust
- Target Recruit Count
- 29
- Registration Number
- NCT00765271
- Locations
- 🇬🇧
Chelsea and Westminster Hospital, London, United Kingdom
Safety and Efficacy Study of Switching From Epzicom to Truvada
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 312
- Registration Number
- NCT00724711
- Locations
- 🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States
🇺🇸Anthony M Mills, MD, Los Angeles, California, United States
🇺🇸Orange Coast Medical Group, Newport Beach, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.